<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097058</url>
  </required_header>
  <id_info>
    <org_study_id>IA0063</org_study_id>
    <secondary_id>R01AG022008</secondary_id>
    <secondary_id>SPO #29004</secondary_id>
    <secondary_id>Grant #R01 AG022008</secondary_id>
    <nct_id>NCT00097058</nct_id>
    <nct_alias>NCT00238589</nct_alias>
  </id_info>
  <brief_title>Estrogen Use in Protection From Cognitive Decline</brief_title>
  <official_title>Estrogen Use in Protection From Cognitive Decline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effects of estrogen therapy among postmenopausal women
      at risk for cognitive decline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 71 postmenopausal women ages 50-65 on estrogen therapy will be randomized to
      continue or discontinue use of estrogen and will be followed for two years.

      Participants will undergo PET and MRI scans and neuropsychological assessments initially and
      at the end of the two-year follow-up period. These procedures will allow us to evaluate brain
      metabolism and cognitive performance at baseline and two years following continuation or
      discontinuation of estrogen therapy.

      We hypothesize that women who discontinue estrogen will show more evidence of decline than
      those who continue estrogen. This project will expand current knowledge of effects of
      estrogen by 1) determining whether estrogen use among postmenopausal women at risk for
      cognitive decline is protective of brain metabolism, 2) identifying early predictors for
      cognitive decline, and 3) developing guidelines for estrogen use in postmenopausal women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cognition and brain metabolism</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Aging</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Continue current hormone therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Taper off hormone therapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood serum urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women between the ages of 45 and 65 years of age, currently on estrogen therapy for 1 year
        prior to enrollment in study, and at risk for cognitive decline.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between the ages of 45 and 65

          -  Currently on hormone replacement

          -  One year or more post complete cessation of menses

          -  Willing to sign the Human Subject Protection Consent form prior to enrollment in the
             study

          -  Willing to be randomized to continue or discontinue estrogen therapy

          -  Adequately visually and auditorially acute to allow neuropsychological testing

          -  Beyond 8 years of educational achievement to allow adequate neuropsychological testing

          -  Willing to undergo brain imaging

          -  At risk for cognitive decline, as defined by one or more of the following: Personal or
             family history of mood disorder, Hypothyroidism, Diabetes, Family history of
             Alzheimer's, APOE-4 allele

        Exclusion Criteria:

          -  Diagnosis of possible or probable Alzheimer's disease or dementia

          -  Cerebrovascular disease or uncontrolled hypertension (systolic BP &gt;170 or diastolic BP
             &gt;100)

          -  History of myocardial infarction within previous year or unstable heart disease

          -  History of significant liver disease, pulmonary disease, or current cancer

          -  Contraindication for MRI (metal in body, claustrophobia, etc.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Rasgon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University School of Medicine, Dept of Psychiatry and Behavioral Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terence Ketter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome Yesavage, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Hoblyn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Palo Alto Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine, Dept. of Psychiatry and Behavioral Sciences</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94070-5723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rasgon NL, Small GW, Siddarth P, Miller K, Ercoli LM, Bookheimer SY, Lavretsky H, Huang SC, Barrio JR, Phelps ME. Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiatry Res. 2001 Jul 1;107(1):11-8.</citation>
    <PMID>11472860</PMID>
  </reference>
  <reference>
    <citation>Rasgon NL, Thomas MA, Guze BH, Fairbanks LA, Yue K, Curran JG, Rapkin AJ. Menstrual cycle-related brain metabolite changes using 1H magnetic resonance spectroscopy in premenopausal women: a pilot study. Psychiatry Res. 2001 Feb 28;106(1):47-57.</citation>
    <PMID>11231099</PMID>
  </reference>
  <reference>
    <citation>Dunkin J, Rasgon N, Wagner-Steh K, David S, Altshuler L, Rapkin A. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women. Psychoneuroendocrinology. 2005 Apr;30(3):284-96.</citation>
    <PMID>15511602</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2004</study_first_submitted>
  <study_first_submitted_qc>November 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2004</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Natalie Rasgon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Menopause</keyword>
  <keyword>Estrogen Replacement Therapy</keyword>
  <keyword>Cognitive Decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

